ClinicalTrials.gg
CompletedNCT03449433Updated Apr 30, 2020Results posted

A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus

A Phase 1 interventional study of LY900014 and Insulin Lispro in Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-30.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.

Enrollment
18th of 69
80 · median 38
Started
2018
with 7 others
Phase 1
22 of 69
none open now
Registered
44th of 69
by date
Lead sponsor
31 of 69
Eli Lilly and Company

Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 18th largest by enrollment, is one of 8 that started in 2018, is one of 22 in phase 1, and was the 44th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by injection under the skin. The study will assess how fast the active ingredient (insulin lispro or insulin aspart) gets into the blood stream and how long it takes the body to remove it. A test meal will be given to trial participants to assess the course of the blood sugar lowering effect of the investigational products. The safety and tolerability of LY900014 will also be assessed. Screening is required within 14 days prior to the lead in. For each participant, the study will last up to 91 days.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are male or female participants with Type 1 Diabetes Mellitus (T1DM) for at least 1 year
  • Have a (BMI) of 18.5 to 35.0 kilogram per meter square (kg/m²)
  • Have a (HbA1c) less than (\<)9.0 percent (%)
  • Have had no episodes of severe hypoglycaemia in the last 6 months

Exclusion criteria

Exclusion Criteria:

  • Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from T1DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the product; or of interfering with the interpretation of data
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    LY900014

    T1DM participants received a single, individualized, subcutaneous (SC) dose of LY900014.

    Drug: LY900014

  • Active comparator
    Insulin Lispro (Humalog®)

    T1DM participants received a single, individualized, SC dose of insulin lispro.

    Drug: Insulin Lispro

  • Active comparator
    Insulin Aspart (NovoRapid®)

    T1DM participants received a single, individualized, SC dose of insulin aspart.

    Drug: Insulin Aspart

  • Active comparator
    Insulin Aspart (Fiasp®)

    T1DM participants received a single, individualized, SC dose of insulin aspart.

    Drug: Insulin Aspart

  • No intervention
    Healthy Participants

    Healthy participants who received no study drug.

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm

    PK: Insulin Lispro or Insulin Aspart AUC(0-7h)

    Time frame: 0 (predose), 1, 2, 3,5,10, 15, 20, 25, 30,35, 40, 45, 50, 55,60, 70, 90, 120, 150,180, 240, 300, 360 and 420 minutes postdose

Secondary outcomes

  1. Pharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)

    PD: AUC(0-5h) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)

    Time frame: Time Frame:-30, -15, 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240, and 300 minutes postdose

07

Results

Posted Apr 30, 2020

Participant flow

Period 1
Participant flow — Period 1
MilestoneType 1 Diabetes Mellitus (T1DM) Cohort 1T1DM Cohort 2T1DM Cohort 3T1DM Cohort 4Healthy Participants
Started1716181712
Received at least 1 dose of study drug171618170
Completed1716181712
Not completed00000
Period 2
Participant flow — Period 2
MilestoneType 1 Diabetes Mellitus (T1DM) Cohort 1T1DM Cohort 2T1DM Cohort 3T1DM Cohort 4Healthy Participants
Started1716181712
Received at least 1 dose of study drug171618170
Completed1716181712
Not completed00000
Period 3
Participant flow — Period 3
MilestoneType 1 Diabetes Mellitus (T1DM) Cohort 1T1DM Cohort 2T1DM Cohort 3T1DM Cohort 4Healthy Participants
Started1716181712
Received at least 1 dose of study drug171518170
Completed1715181712
Not completed01000
Period 4
Participant flow — Period 4
MilestoneType 1 Diabetes Mellitus (T1DM) Cohort 1T1DM Cohort 2T1DM Cohort 3T1DM Cohort 4Healthy Participants
Started1715181712
Received at least 1 dose of study drug171518170
Completed1715181712
Not completed00000

Outcome measures

PrimaryPharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm

PK: Insulin Lispro or Insulin Aspart AUC(0-7h)

Time frame:
0 (predose), 1, 2, 3,5,10, 15, 20, 25, 30,35, 40, 45, 50, 55,60, 70, 90, 120, 150,180, 240, 300, 360 and 420 minutes postdose
Reported as:
Geometric mean · picomols times hour per Liter
Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm
picomols times hour per LiterLY900014Insulin Lispro (Humalog®)Insulin Aspart (NovoRapid®)Insulin Aspart (Fiasp®)
Pharmacokinetics (PK): Insulin Lispro or Insulin Aspart Area Under the Concentration Curve From Zero to Seven Hours (AUC 0-7h) Following Administration of Each Study Arm786 ± 36756 ± 37938 ± 41928 ± 36
Statistical analysis
  • LY900014 vs Insulin Lispro (Humalog®) · Ratio of ls means: 1.04 · 95% CI 0.985 to 1.10
SecondaryPharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)

PD: AUC(0-5h) of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)

Time frame:
Time Frame:-30, -15, 0 (predose), 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240, and 300 minutes postdose
Reported as:
Mean · milligrams times hour per deciliter
Pharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)
milligrams times hour per deciliterLY900014Insulin Lispro (Humalog®)Insulin Aspart (NovoRapid®)Insulin Aspart (Fiasp®)Healthy Participants
Pharmacodynamics (PD): Change From Baseline Area Under the Concentration Curve of Glucose Relative to a Mixed Meal Tolerance Test (MMTT)81.5 ± 212141 ± 224157 ± 243101 ± 22644.1 ± 32.5

Adverse events

Collected over up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY9000140/68 (0%)0/68 (0%)0/68 (0%)
Insulin Lispro (Humalog®)0/67 (0%)0/67 (0%)0/67 (0%)
Insulin Aspart (Fiasp®)0/68 (0%)0/68 (0%)0/68 (0%)
Insulin Aspart (NovoRapid®)0/67 (0%)0/67 (0%)0/67 (0%)
Healthy Participants0/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

All randomized participants that received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)T1DM CohortHealthy ParticipantsTotal
<=18 years000
Between 18 and 65 years611273
>=65 years707
Sex: Female, Male
Sex: Female, Male(Participants)T1DM CohortHealthy ParticipantsTotal
Female17017
Male511263
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)T1DM CohortHealthy ParticipantsTotal
Hispanic or Latino101
Not Hispanic or Latino671279
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)T1DM CohortHealthy ParticipantsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White681280
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)T1DM CohortHealthy ParticipantsTotal
Germany68120
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter squared)T1DM CohortHealthy ParticipantsTotal
Mean25.82 ± 2.3625.38 ± 1.8025.38 ± 1.80
08

Study locations

1 site
  • Profil Institut für Stoffwechselforschung
    Neuss, Nordrhein-Westfalen 41460, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Aug 2018, 4 months.

Results were first posted in Apr 2020, 1 year 8 months after primary completion.

Of 98 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 4 months is below that.

Counting every sponsor, half of 153 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2018
First posted
Feb 28, 2018
StartActual
Mar 15, 2018
Primary completionActual
Aug 14, 2018
CompletionActual
Aug 14, 2018
Results first posted
Apr 30, 2020
Last update
Apr 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03449433
Responsible party
Sponsor
First posted
Feb 28, 2018
Start date
Mar 15, 2018
Primary completion
Aug 14, 2018
Completion
Aug 14, 2018
Results posted
Apr 30, 2020
Last update
Apr 30, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Lispro

Start the discussion